Aducanumab Produced a Clinically Meaningful Benefit in Association With Amyloid Lowering

Authors

Jeffrey Cummings, University of Nevada, Las VegasFollow
Paul Aisen, University of Southern California
Cynthia Lemere, Harvard Medical School
Alireza Atri, Banner Sun Health Research Institute
Marwan Sabbagh, Cleveland Clinic Lou Ruvo Center for Brain Health
Stephen Salloway, Butler Hospital

Document Type

Letter to the Editor

Publication Date

5-10-2021

Publication Title

Alzheimer's Research and Therapy

Volume

13

Issue

1

First page number:

1

Last page number:

3

Keywords

Aducanumab; Clinical trials; Donanemab; FDA; Gantenerumab; Lecanemab; Monoclonal antibodies

Disciplines

Cognitive Neuroscience

File Format

pdf

File Size

803 KB

Language

English

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 License.

Repository Citation

Cummings, J., Aisen, P., Lemere, C., Atri, A., Sabbagh, M., Salloway, S. (2021). Aducanumab Produced a Clinically Meaningful Benefit in Association With Amyloid Lowering. Alzheimer's Research and Therapy, 13(1), 1-3.
http://dx.doi.org/10.1186/s13195-021-00838-z